ConjuChem Appoints Vice President, General Counsel

    - Ms. Jean Silveri to Assume Responsibilities Effective Immediately -

    MONTREAL, Sept. 4 /CNW/ - ConjuChem Biotechnologies Inc. (TSX:CJB) today
announced the appointment of Ms. Jean Silveri as Vice President, General
Counsel effective immediately. Ms. Silveri will be responsible for the ongoing
development and execution of ConjuChem's legal and intellectual property
strategies and contribute to the Company's overall strategic direction.
    Ms. Silveri joins ConjuChem after nine years at Millennium
Pharmaceuticals, Inc., where she most recently served as Associate General
Counsel. In her tenure at Millennium, Ms. Silveri was responsible for advising
the senior management team, business development group, and various commercial
groups on matters related to intellectual property prosecution and litigation
strategies, management of pharmaceutical partner relationships under
Millennium's various collaboration agreements, product life cycle management
strategies, and numerous product and company acquisition strategies. She was
also responsible for creating the international intellectual property
portfolio around the company's biologic clinical candidates.
    Prior to joining Millennium, Ms. Silveri was an associate at the Boston
law firm of Lahive & Cockfield where she specialized in the preparation,
prosecution, and maintenance of international biotechnology patent portfolios
and the preparation of legal opinions related to intellectual property rights.
She received a B.A. in Biology from Assumption College, an M.A. in Cellular
and Molecular Physiology from Harvard University, and a J.D. from Suffolk
University Law School. She is admitted to practice in Massachusetts, the
District of Columbia, and the United States Patent and Trademark Office.

    About ConjuChem Biotechnologies

    ConjuChem Biotechnologies, developer of next generation medicines from
therapeutic peptides, is creating long-acting compounds based on
bioconjugation platform technologies. When applied to peptides, the Company's
systemic DAC(TM) and PC-DAC(TM) Technologies enable the creation of new drugs
with significantly enhanced therapeutic properties as compared to the original
peptide. Detailed descriptions of the Company can be viewed on the Company's

    Forward-Looking Statements

    Some of the statements made herein may constitute forward-looking
statements. These statements relate to future events or our future financial
performance and involve known and unknown risks, uncertainties and other
factors that may cause ConjuChem Biotechnologies' actual results, performance
or achievements to be materially different from those expressed or implied by
any of the Company's statements. Actual events or results may differ
materially. We disclaim any intention, and assume no obligation, to update
these forward-looking statements.

For further information:

For further information: Lennie Ryer, CA, Vice President, Finance & CFO,
ConjuChem Biotechnologies Inc., (514) 844-5558, ext. 224,;
James Smith, Investor Relations, (416) 815-0700, ext. 229,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890